Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. Its technology platforms include AVERSION, IMPEDE, and LIMITX. The company was founded on April 10, 1935 and is headquartered in Palatine, IL.

Company profile
Ticker
ACUR
Exchange
Website
CEO
Robert Jones
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HALSEY DRUG CO INC/NEW
SEC CIK
Corporate docs
IRS number
110853640
ACUR stock data
Investment data
Securities sold
Number of investors
Calendar
16 May 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 89K | 89K | 89K | 89K | 89K | 89K |
Cash burn (monthly) | 26K | 33.67K | 177K | 118.33K | (no burn) | 33K |
Cash used (since last report) | 271.65K | 351.75K | 1.85M | 1.24M | n/a | 344.78K |
Cash remaining | -182.65K | -262.75K | -1.76M | -1.15M | n/a | -255.78K |
Runway (months of cash) | -7.0 | -7.8 | -9.9 | -9.7 | n/a | -7.8 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Aug 22 | Peter A Clemens | Common Stock | Option exercise | Acquire M | No | No | 0 | 49,333 | 0 | 465,430 |
3 Aug 22 | Peter A Clemens | RSU Common Stock | Option exercise | Acquire M | No | No | 0.01 | 40,000 | 400 | 80,000 |
3 Aug 22 | Peter A Clemens | RSU Common Stock | Option exercise | Acquire M | No | No | 0.01 | 9,333 | 93.33 | 120,000 |
3 Aug 22 | Robert B Jones | Common Stock | Option exercise | Acquire M | No | No | 0 | 63,666 | 0 | 553,555 |
3 Aug 22 | Robert B Jones | RSU Common Stock | Option exercise | Acquire M | No | No | 0.01 | 50,000 | 500 | 90,000 |
3 Aug 22 | Robert B Jones | RSU Common Stock | Option exercise | Acquire M | No | No | 0.01 | 13,666 | 136.66 | 140,000 |
3 Aug 22 | Robert A Seiser | Common Stock | Option exercise | Acquire M | No | No | 0 | 24,666 | 0 | 378,254 |
3 Aug 22 | Robert A Seiser | RSU Common Stock | Option exercise | Acquire M | No | No | 0.01 | 20,000 | 200 | 60,000 |
3 Aug 22 | Robert A Seiser | RSU Common Stock | Option exercise | Acquire M | No | No | 0.01 | 4,666 | 46.66 | 80,000 |
3 Aug 22 | Albert W Brzeczko | Common Stock | Option exercise | Acquire M | No | No | 0 | 43,333 | 0 | 412,001 |
Institutional ownership, Q4 2021
81.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 21.49M |
Total shares | 52.99M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Schutte John | 52.98M | $21.49M |
Lenox Wealth Advisors | 780 | $0 |
Financial report summary
?Competition
Pfizer • Nektar Therapeutics • Elite Pharmaceuticals • Cassava Sciences • Acelrx Pharmaceuticals • KemPharm • PerrigoContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Letter, physiologic, Sep, stringent
Removed:
accruing, beginning, commitment, disbursement, epidemiology, granting
Current reports
8-K
Other Events
28 Jul 22
8-K
Entry into a Material Definitive Agreement
19 Jul 22
8-K
Other Events
14 Jul 22
8-K
Entry into a Material Definitive Agreement
11 Jul 22
8-K
Entry into a Material Definitive Agreement
13 Jun 22
8-K
Entry into a Material Definitive Agreement
23 May 22
8-K
Other Events
19 May 22
8-K
Entry into a Material Definitive Agreement
2 May 22
8-K
Entry into a Material Definitive Agreement
4 Apr 22
8-K
Entry into a Material Definitive Agreement
1 Mar 22
Registration and prospectus
S-8
Registration of securities for employees
1 Jun 21
RW
Registration withdrawal request
31 Jul 18
S-8
Registration of securities for employees
16 Nov 17
D
$4M in equity / options / securities to be acquired, sold $4M, 1 investor
27 Jul 17
25-NSE
Exchange delisting
13 Mar 17
S-1
IPO registration
2 Feb 17
S-8
Registration of securities for employees
8 Aug 16
S-3/A
Shelf registration (amended)
22 Mar 16
S-3
Shelf registration
8 Mar 16
424B5
Prospectus supplement for primary offering
30 Jun 15
Proxies
Other
CT ORDER
Confidential treatment order
9 Apr 18
CT ORDER
Confidential treatment order
14 Jun 17
EFFECT
Notice of effectiveness
29 Mar 16
CORRESP
Correspondence with SEC
24 Mar 16
UPLOAD
Letter from SEC
17 Mar 16
CT ORDER
Confidential treatment order
23 Feb 16
CT ORDER
Confidential treatment order
4 May 15
UPLOAD
Letter from SEC
16 Oct 14
CORRESP
Correspondence with SEC
14 Oct 14
CORRESP
Correspondence with SEC
28 Sep 14
Ownership
4
ACURA PHARMACEUTICALS / Albert W Brzeczko ownership change
5 Aug 22
4
ACURA PHARMACEUTICALS / Robert B Jones ownership change
5 Aug 22
4
ACURA PHARMACEUTICALS / Robert A Seiser ownership change
5 Aug 22
4
ACURA PHARMACEUTICALS / PETER A CLEMENS ownership change
5 Aug 22
4
ACURA PHARMACEUTICALS / Robert A Seiser ownership change
18 Mar 22
4
ACURA PHARMACEUTICALS / Robert B Jones ownership change
18 Mar 22
4
ACURA PHARMACEUTICALS / PETER A CLEMENS ownership change
18 Mar 22
4
ACURA PHARMACEUTICALS / Albert W Brzeczko ownership change
18 Mar 22
SC 13D/A
ACURA PHARMACEUTICALS / ESSEX WOODLANDS HEALTH VENTURES FUND V ownership change
14 Feb 22
4
ACURA PHARMACEUTICALS / IMMANUEL THANGARAJ ownership change
12 Jan 22
Patents
Utility
Methods and Compositions for Interfering with Extraction or Conversion of a Drug Susceptible to Abuse
3 Mar 22
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
Utility
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
14 Dec 21
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
Utility
Methods and Compositions for Self-regulated Release of Active Pharmaceutical Ingredient
28 Oct 21
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
31 Aug 21
An abuse deterrent pharmaceutical composition including an acid soluble salt of a pharmaceutically active ingredient and a buffering ingredient; wherein the acid soluble salt of the pharmaceutically active ingredient and the buffering ingredient retard release of the pharmaceutically active ingredient when the composition is ingested in excess of an intended dosage.
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
10 Aug 21
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.